Tenecteplase, a drug that has been used for the treatment of acute myocardial infarction for several decades, recently showed promising results in acute ischemic stroke, while little is known on the population pharmacokinetics in that population.
Jurgen Langenhorst and Mats Magnusson, together with their collaborators at Genentech, sought to leverage available data in acute myocardial infarction to predict summary pharmacokinetic data of patients with acute ischemic stroke.
The developed pharmacokinetics model including relevant covariates allowed to simulate the new patient population and determine the absence of evidence of clinically relevant differences that would warrant dose adjustments within patients with acute ischemic stroke.
Publication title: Population Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic Stroke
Pharmetheus affiliates: Jurgen Langenhorst and Mats Magnusson